Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taro Pharmaceutical Industries has settled a pending lawsuit with Novartis and will be launching Oxcarbazepine tablets 150mg, 300 mg, and 600mg in the US.
Subscribe to our email newsletter
Oxcarbazepine tablets, marketed by Novartis as Trileptal tablets, are prescription pharmaceutical products used in treating seizures. Taro has recently settled litigation with Novartis regarding Taro’s ‘Paragraph IV’ certification challenging Novartis’s patent protection on Trileptal.
On November 15, 2007, Taro received approval from the FDA for its abbreviated new drug application for Oxcarbazepine tablets 150mg, 300mg, and 600mg. The company did not immediately launch the product at that time, pending settlement of the litigation with Novartis.